华兴证券发表报告指，药明生物(02269.HK) 2024年公司业绩符合预期，未来有望实现稳健增长。根
据公司2024年报告，2014至2024年公司非新冠收入覆合增长率超过50%。随着生产工艺持续优化和效率不断提升，以及全球布局的进一步完善，公司预计2025年收入有望实现按年增长12%-15%。
该行预计，公司2025至2027年收入与利润将保持上升趋势，分别为13.4%、18.9%、18.4%和 10.7%、18.6%及16.7%。重申“买入”评级，目标价由26.12元升至33.4元。(ha/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-01 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.